

QUADRON CAPITAL CORPORATION

Suite 1600 - 609 Granville Street

Vancouver, BC V7Y 1C3

Phone: 1-866-824-8938

News Release

QUADRON COMPLETES AMALGAMATION WITH SOMA LABS SCIENTIFIC INC.

Vancouver, British Columbia, January 11, 2016: Quadron Capital Corporation (the "Company" or "Quadron") is pleased to announce that, pursuant to the definitive amalgamation agreement executed November 6, 2015, a wholly-owned subsidiary of Quadron has completed the amalgamation (the "Acquisition") with Soma Labs Scientific Inc. ("Soma Labs"). Soma Labs is an arms' length private company incorporated under the laws of British Columbia.

Soma Labs is a BC-based laboratory and research facility that provides services to the biotech and bioceutical industries. Soma Labs, pursuant to a services contract with Odorchem Manufacturing Corp., is providing research for the scientific development of new odor control processes and formulations. Soma Labs is also leveraging its operations and scientific personnel to expand further into the cannabis industry, a burgeoning market segment within Canada. Soma Labs' initial focus will be on deriving revenues from the development and refinement of the cannabis extraction process.

"These are very exciting times for Quadron", states Rosy Mondin, newly appointed President and CEO of the Company. "2016 is the start of a transformative era as Canada embarks upon the legalization of cannabis. As the cannabis industry continues to develop, the ability to produce safe, high-quality products and services for patients and clients is required. Quadron's goal is to focus on revenue generating opportunities by working with industry participants to advance the scientific research and development of evidence-based cannabis products. As well, Quadron intends to actively seek out acquisition opportunities that will allow us to quickly establish ourselves as an industry leader."

For more information, visit: www.somalabs.ca

Security holders of Soma Labs received 17,422,500 common shares and 2,000,000 preferred shares of Quadron in exchange for all of their common and preferred shares of Soma Labs. Subject to Soma Labs achieving \$1,000,000 in earnings before interest, taxes, depreciation and amortization for the fiscal year ending April 30, 2017, each preferred share will automatically convert into one common share of Quadron. The holders of Soma Labs' convertible securities also received convertible securities of Quadron on a one-for-one basis.

As part of the Acquisition, the board of directors of Quadron has been reconstituted to comprise of the following persons: Doug McFaul, Rosy Mondin, Scott Ackerman and Jeff Durno. Management of Quadron shall comprise of Rosy Mondin – President and Chief Executive Officer; and Robert Chisholm – Chief Financial Officer.

The amalgamation follows the recent closing by Quadron of a non-brokered private placement of 4,637,500 units at \$0.10 per unit for gross proceeds of \$463,750. Each unit is comprised of one common share and one-half of one share purchase warrant. Each whole warrant entitles the holder to purchase one additional common share of the Company at a price of \$0.20 per share for 24 months from the date of issuance. If at any time during the 24 months, Quadron completes a going public

transaction, the expiry date will be amended to 18 months following the closing of the going public transaction. All the securities issued in the financing have a 4 month hold period expiring May 1, 2016. Following these transactions, Quadron has 36,500,000 shares issued and outstanding and 48,500,000 shares fully diluted.

For further information, contact Doug McFaul at (778) 331-8505.

On behalf of the Board of Directors of
QUADRON CAPITAL CORPORATION

Rosy Mondin
Director

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.